Get started
Ionis Pharmaceuticals, Inc.II

Ionis Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

IONS trade ideas

Analyzing the options chain and the chart patterns of PENN EnterAnalyzing the options chain and the chart patterns of UPS United Parcel Service prior to the earnings report this week, I would consider purchasing the $42.50 strike price Calls with an expiration date of 2023-8-18, for a premium of approximately $0.37. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NLong
by TopgOptions
Ionis Pharma (IONS) - Frequency Formula Strategy - LongStrategy Overview: The Frequency Formula Our trading strategy, "The Frequency Formula," is built on cutting-edge Fourier Wave Transform theory. The strategy utilizes four unique indicators: the Frequency Formula Chop Indicator (FF-CI), Frequency Formula Trend Indicator (FF-TI), the Frequency Formula Volume Indicator with Combined Ratios (FFVI-CR), and the Frequency Formula Net Buy/Net Sell Volume Indicator (FF-NBNS). Together, they identify optimal entry and exit points based on changes in market trends, volumes, and sentiments. Why Now Is a Good Time to Enter The FF-CI and FF-TI suggest that the current market chop and previous bearish trend are transitioning into a solid upward trend. Simultaneously, the FF-UVI-CR indicates increased buying volume and positive sentiment, suggesting strong support for the upward price movement. What to Look for When Exiting Keep an eye on our FF-VMI-CR and FF-NBNS Indicators. When the FF-VMI-CR indicator positive volume (blue) and negative volume (red) signals converge or "squeeze", this indicates a significant increase in net selling volume and might indicate a potential trend reversal; also, watch the FF-NBNS indicator's net-selling value (red) to increase and close at any value greater than zero, at this point you should exit the position. Remember to always manage your risk, and don't invest more than you can afford to lose. Happy trading!
NLong
by H3l10s
bottom fishing"George Lane identified another form of divergence to predict bottoms or tops, dubbed “set-ups.” A bull set-up is basically the inverse of a bullish divergence. The underlying security forms a lower high, but the Stochastic Oscillator forms a higher high. Even though the stock could not exceed its prior high, the higher high in the Stochastic Oscillator shows strengthening upside momentum. The next decline is then expected to result in a tradable bottom." A bear set-up occurs when the security forms a higher low, but the Stochastic Oscillator forms a lower low. Even though the stock held above its prior low, the lower low in the Stochastic Oscillator shows increasing downside momentum. The next advance is expected to result in an important peak.
NLong
by KhanhC.Hoang
2
On high priority watch list - potential buy opportunityDown trend since January highs after 1st qtr company report. Overall price has dropped over 45%. Potential consolidation with trend reversal. This stock has been on my radar the last 2-3 weeks as I have been evaluating and looking for signs of a reversal before going long. Ratings/analysis are mixed for this stock. I believe there is substantial uncertainty with this stock, but strong upside potential and is probably under valued. There is a high probability I will go long, I am just looking for my entry point.
N
by JLJ002500
Ionis Pharmaceuticals Inc 🧙Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NLong
by trading_as_bus
PREDICTION 3 #IONS - NASDAQ - SELL! UP TO 14% PROFIT!Hi Followers, Welcome to my page, I will be posting 10 charts on USA #STOCK #MARKET this month. #STOCKMARKET Using a Unique Technical Analysis invented by me. Later, if the charts work out, I will talk more about it. As far as our technical Analysis is identifying, there is a big possibility that this company is OVERBOUGHT, which opens a trade opportunity. This could lead allow up to 14% profit and could end in 20 days. About the Company: #IONS - #NASDAQ Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardiometabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardiometabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hypertension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Good Luck and Good Profit
NShort
by UnknownUnicorn5368510
All the Longs Will Continue to be WrongIn reviewing previous ideas on here I was stunned to see how many folks called this long. But I guess you can read into a chart whatever you like. Although could be concerned about double bottom, it is very apparent that IONS is doing nothing but going down. I see this as a flag wth potential to seem 48 before it’s done (although 52.5-55 more likely). Either way chart shows no chance of breaking upwards. Will be buying May 31 60 Put June 7 55 Put Believe both will have nice upside by Weds. Volume was way up on Friday and very little recovery after sizable drop. Don’t see any recovery Tuesday. Great opportunity for short term gain on these two Puts
NShort
by grubby1220